Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Immunosuppression by hypoxic cell radiosensitizers: a phenomenon of potential clinical importance

Journal Article · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)
The nitroimidazoles metronidazole, misonidazol, and desmethyl misonidazole are currently undergoing clinical trials as possible adjuncts to radiotherapy. Ongoing clinical trials are evaluating the effectiveness of these agents and also documenting the pharmacokinetics and toxicities of radiosensitizing doses of these drugs in man. A variety of toxic effects have been noted in man, including anorexia, nausea and vomiting, peripheral neuropathy, central nervous system symptoms, ototoxicity, allergy, and fear. Laboratory studies have also suggested that these agents have potential to be mutagenic, carcinogenic, and teratogenic. In the editorial presented, the author attempts to draw attention to an additional toxic effect of nitroimidazoles - the inhibition of cell-mediated immune responses. (JMT)
Research Organization:
Yale Univ. School of Medicine, New Haven, CT
OSTI ID:
6714357
Journal Information:
Int. J. Radiat. Oncol., Biol. Phys.; (United States), Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Vol. 8:6; ISSN IOBPD
Country of Publication:
United States
Language:
English